Eyebio Announces Expansion Of Series A To $130 Million, Advances Development Of Restoret For Retinal Diseases
Round Type
Series A
Investors
Description
Eyebiotech Limited (“EyeBio” or “the Company”), a privately held clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the Company’s clinical development program and further build out its innovative retina pipeline.
Quick answer
EyeBio raised an undisclosed amount in a Series A round, dated November 14, 2023. Investors: MRL Ventures Fund, Samsara Biocapital, Jeito Capital, SV Health Investors, Vertex Ventures HC, Omega Funds and Bain Capital Life Sciences.
- How much did EyeBio raise?
- EyeBio raised an undisclosed amount in a Series A round on November 14, 2023.
- Who invested in EyeBio?
- MRL Ventures Fund, Samsara Biocapital, Jeito Capital, SV Health Investors, Vertex Ventures HC, Omega Funds and Bain Capital Life Sciences are named as investors in this round.
- What does EyeBio do?
- EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
- Who are the decision-makers at EyeBio?
- Fundz holds 1 contact at EyeBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as EyeBio that raised within 45 days of this round, from Fundz verified event records.
- On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
- MAIA Biotechnology raised $4.9M (Seed) on November 15, 2023.
- MBrace Therapeutics raised $85M (Series B) on November 14, 2023.
- Ascidian Therapeutics raised $40M (Series A) on November 8, 2023.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
- Actym Therapeutics raised $60M (Series A) on October 18, 2023.
Who to call at EyeBio, and when
A new round usually means EyeBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day EyeBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at EyeBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at EyeBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EyeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEyeBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.